FindTrial
Sign In

RSVPreF3 OA vaccine

BIOLOGICAL4 trials

Sponsors

GlaxoSmithKline

Conditions

Respiratory Syncytial Virus Infections

Phase 3

Efficacy Study of GSK's Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above
CompletedNCT04886596
GlaxoSmithKlineRespiratory Syncytial Virus Infections
Start: 2021-05-25End: 2024-05-31Updated: 2025-07-31
A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone or Co-administered With an Adjuvanted Vaccine Against Influenza in Adults Aged 65 Years and Above
CompletedNCT05568797
GlaxoSmithKlineRespiratory Syncytial Virus Infections
Start: 2022-10-14End: 2023-07-17Updated: 2024-09-24
An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 60 Years of Age and Above Who Participated in RSV OA=ADJ-006 Study
Active, not recruitingNCT06534892
GlaxoSmithKlineRespiratory Syncytial Virus Infections
Start: 2024-08-01End: 2026-09-30Updated: 2026-07-29
A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus Given to Chinese Adults 18 to 59 Years of Age at Increased Risk of Respiratory Syncytial Virus Disease
Active, not recruitingNCT07220109
GlaxoSmithKlineRespiratory Syncytial Virus Infections
Start: 2025-10-29End: 2026-12-31Updated: 2026-08-03

Related Papers

Estimated efficacy of the adjuvanted RSVPreF3 vaccine against diverse and worldwide predominant RSV strains, irrespective of RSV F protein variation: results of a post-hoc analysis from the AReSVi-006 trial
EBioMedicine2026-05-22
Cost-effectiveness of the adjuvanted respiratory syncytial virus prefusion F protein (RSVPreF3) vaccine in Japanese adults aged 50-59 years at increased risk of severe RSV disease and those aged ≥60 years.
2026-02-11
Efficacy, safety, and immunogenicity of the AS01<sub>E</sub>-adjuvanted respiratory syncytial virus prefusion F protein vaccine (RSVPreF3 OA) in older adults over three respiratory syncytial virus seasons (AReSVi-006): a multicentre, randomised, observer-blinded, placebo-controlled, phase 3 trial.
2025-04-1415 citations
219. Robust and Consistent Immune Response of the Adjuvanted Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine (RSVPreF3 OA) Across Different Age Ranges and Frailty Status in Older Adults
Open Forum Infectious Diseases2025-01-29
MODELAGEM DA CARGA DE SAÚDE PÚBLICA DO VÍRUS SINCICIAL RESPIRATÓRIO E O IMPACTO DA VACINA VSR ADJUVANTADA (RSVPREF3) EM ADULTOS COM 60 ANOS OU MAIS NO BRASIL
The Brazilian Journal of Infectious Diseases2024-11-01
Safety and Immunogenicity of Respiratory Syncytial Virus Prefusion F Protein Vaccine when Co-administered with Adjuvanted Seasonal Quadrivalent Influenza Vaccine in Older Adults: A Phase 3 Randomized Trial
Clinical Infectious Diseases2024-08-0514 citations
The respiratory syncytial virus prefusion F protein vaccine attenuates the severity of respiratory syncytial virus‐associated disease in breakthrough infections in adults ≥60 years of age
Influenza and Other Respiratory Viruses2024-02-0123 citations
Efficacy and Safety of Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine (RSVPreF3 OA) in Older Adults Over 2 RSV Seasons
Clinical Infectious Diseases2024-01-22133 citations
The potential public health impact of the respiratory syncytial virus prefusion F protein vaccine in people aged ≥60 years in Japan: results of a Markov model analysis.
2024-01-019 citations
1936. Efficacy of One Dose of the Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine (RSVPreF3 OA) in Adults ≥ 60 Years of Age Persists for 2 RSV Seasons
Open Forum Infectious Diseases2023-11-2710 citations
Respiratory Syncytial Virus Prefusion F Protein Vaccine Is Efficacious in Older Adults With Underlying Medical Conditions
Clinical Infectious Diseases2023-09-1245 citations
Safety and Immunogenicity of a Revaccination With a Respiratory Syncytial Virus Prefusion F Vaccine in Older Adults: A Phase 2b Study
The Journal of Infectious Diseases2023-09-1219 citations
Late Breaking Abstract - Efficacy of a respiratory syncytial virus (RSV) prefusion F protein vaccine (RSVPreF3 OA) in older adults with co-existing cardiorespiratory conditions
2023-09-093 citations
280-LB: Efficacy of a Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine (RSVPreF3 OA) in Older Adults with Preexisting Medical Conditions
Diabetes2023-06-206 citations
Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults
New England Journal of Medicine2023-02-15661 citations
LB745. Respiratory Syncytial Virus (RSV) Prefusion F Protein Candidate Vaccine (RSVPreF3 OA) is Efficacious in Adults ≥ 60 Years of Age (YOA)
Open Forum Infectious Diseases2022-12-016 citations
Safety and Immunogenicity of a Respiratory Syncytial Virus Prefusion F (RSVPreF3) Candidate Vaccine in Older Adults: Phase 1/2 Randomized Clinical Trial
The Journal of Infectious Diseases2022-07-29108 citations